ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2022 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP – Get Rating) updated its FY 2022 earnings guidance on Tuesday. The company provided earnings per share guidance of $1.34-$1.62 for the period, compared to the consensus earnings per share estimate of $1.15. The company issued revenue guidance of $295.00 million-$315.00 million, compared to the consensus revenue estimate of $292.77 million. Several […]

Related Keywords

United States ,Canada ,Nikhil Lalwani ,Raymond James ,Patrickd Walsh ,Securities Exchange Commission ,Zacks Investment Research ,Pharmaceuticals Get Rating ,York Mellon Corp ,Charles Schwab Investment Management Inc ,Cantor Fitzgerald ,Pharmaceuticals Inc ,Citigroup Inc ,Millennium Management ,Ani Pharmaceuticals ,Get Rating ,Investment Research ,Director Patrick ,Exchange Commission ,New York Mellon Corp ,Charles Schwab Investment Management ,Schwab Investment Management ,Nasdaq Anip ,Manip ,Medical ,Guidance ,Earnings ,Preannouncement ,